The development of therapeutic strategies to target the Fas pro-survival signaling, such as by neutralizing the pro-survival soluble FasL12 and/or co-inhibition of Src family kinases and STAT3, may represent a rational approach for combinatory or sequential cancer therapies to delay disease recurrence and prolong disease-free survival. Here, STAT3 is linked to cancer.